![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » BANYU, MARUHO RECEIVE NHI APPROVAL FOR ORAL SCABIES MEDICATION
BANYU, MARUHO RECEIVE NHI APPROVAL FOR ORAL SCABIES MEDICATION
August 29, 2006
Banyu Pharmaceutical and Maruho Co., Ltd. have announced that an additional indication of Stromectol Tablets 3mg -- generic name ivermectin -- has been approved for the administration for scabies treatment under the Nippon Health Insurance (NHI) system, alleviating patients' payment for the drug themselves. JCN Network (http://www.japancorp.net/Article.Asp?Art_ID=13112)
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct